IOL Chemicals & Pharmaceuticals Ltd. (IN:IOLCP)
:IOLCP
Want to see IN:IOLCP full AI Analyst Report?
Top Page
IOL Chemicals & Pharmaceuticals Ltd.
(IOLCP)
Select Model
Select Model
Rating:67Neutral
Price Target:
₹148.00
â–²(76.00% Upside)
Action:Reiterated
Date:05/27/26
The score is driven mainly by moderate financial performance: a strong, low-leverage balance sheet is offset by materially lower margins versus FY2021 and volatile/free-cash-flow weakness. Technicals are a positive with a strong uptrend, though momentum is elevated (higher pullback risk). Valuation is reasonable on P/E but supported less by a low dividend yield.
Positive Factors
Conservative Balance Sheet
Low leverage and a materially larger equity base provide enduring financial resilience. This structural strength reduces funding costs, increases capacity to absorb shocks, and preserves optionality for strategic investment or targeted M&A without materially increasing solvency risk.
Negative Factors
Material Margin Compression
Sharp erosion from prior peaks indicates lasting pressure on pricing, mix, or cost structure. Lower margins reduce retained earnings, constrain reinvestment or dividend capacity, and signal potential structural competitiveness issues that could persist absent margin recovery or cost transformation.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Low leverage and a materially larger equity base provide enduring financial resilience. This structural strength reduces funding costs, increases capacity to absorb shocks, and preserves optionality for strategic investment or targeted M&A without materially increasing solvency risk.
Read all positive factors
IOL Chemicals & Pharmaceuticals Ltd. (IOLCP) vs. iShares MSCI India ETF (INDA)
Market Cap
₹37.63B
Dividend Yield0.97%
Average Volume (3M)113.78K
Price to Earnings (P/E)27.4
Beta (1Y)1.63
Revenue Growth11.54%
EPS Growth36.15%
CountryIN
Employees2,777
SectorBasic Materials
Sector Strength58
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)3.95
Shares Outstanding293,527,500
10 Day Avg. Volume248,884
30 Day Avg. Volume113,785
Financial Highlights & Ratios
PEG Ratio0.43
Price to Book (P/B)1.19
Price to Sales (P/S)0.92
P/FCF Ratio55.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)6.7
Revenue Forecast (FY)₹26.48B
IOL Chemicals & Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Established in 1986 and headquartered in Ludhiana, India, IOL Chemicals and Pharmaceuticals Limited operates as a global manufacturer and supplier of diverse pharmaceutical and chemical products. Its pharmaceutical portfolio encompasses a wide arr...
How the Company Makes Money
IOLCP primarily makes money by manufacturing and selling products from two main business segments: (1) Pharmaceuticals—revenue is generated from sales of APIs to pharmaceutical formulators and other buyers in domestic and export markets; and (2) C...
IOL Chemicals & Pharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
82
Very Positive
Cash Flow
45
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 21.70B | 23.19B | 20.68B | 21.19B | 22.02B | 21.84B |
| Gross Profit | 7.38B | 5.03B | 6.54B | 2.70B | 6.41B | 5.72B |
| EBITDA | 2.52B | 2.69B | 2.25B | 2.61B | 2.46B | 2.71B |
| Net Income | 1.16B | 1.38B | 1.01B | 1.34B | 1.39B | 1.68B |
Balance Sheet | ||||||
| Total Assets | 24.13B | 25.87B | 23.82B | 22.44B | 20.22B | 19.62B |
| Cash, Cash Equivalents and Short-Term Investments | 1.79B | 2.02B | 2.09B | 1.43B | 186.40M | 1.20B |
| Total Debt | 1.59B | 1.35B | 1.17B | 327.60M | 798.10M | 439.50M |
| Total Liabilities | 6.62B | 7.88B | 6.94B | 6.33B | 5.14B | 5.70B |
| Stockholders Equity | 17.51B | 17.99B | 16.88B | 16.12B | 15.08B | 13.92B |
Cash Flow | ||||||
| Free Cash Flow | -535.70M | 384.30M | -349.30M | 159.10M | -895.50M | -602.40M |
| Operating Cash Flow | 110.60M | 2.11B | 1.79B | 2.90B | 1.22B | 930.50M |
| Investing Cash Flow | -961.60M | -2.10B | -1.54B | -1.91B | -1.20B | -1.21B |
| Financing Cash Flow | 342.30M | -145.00M | 460.40M | -925.00M | -41.10M | -16.40M |
IOL Chemicals & Pharmaceuticals Ltd. Technical Analysis
Positive
84.09
Price Trends
108.59
Positive
90.93
Positive
91.69
Positive
Market Momentum
5.66
Positive
56.13
Neutral
20.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:IOLCP, the sentiment is Positive. The current price of 84.09 is below the 20-day moving average (MA) of 129.02, below the 50-day MA of 108.59, and below the 200-day MA of 91.69, indicating a neutral trend. The MACD of 5.66 indicates Positive momentum. The RSI at 56.13 is Neutral, neither overbought nor oversold. The STOCH value of 20.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:IOLCP.
IOL Chemicals & Pharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | ₹220.83B | 60.70 | ― | 0.08% | 36.98% | 39.94% | |
67 Neutral | ₹37.63B | 27.38 | ― | 0.97% | 11.54% | 36.15% | |
66 Neutral | ₹193.86B | 32.19 | ― | 0.24% | 19.73% | 18.17% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
60 Neutral | ₹33.79B | 17.32 | ― | 0.24% | 7.47% | 16.13% | |
52 Neutral | ₹27.10B | -334.22 | ― | ― | 6.64% | -177.19% | |
50 Neutral | ₹24.48B | -50.09 | ― | 0.58% | -7.91% | -153.72% |
* Basic Materials Sector Average
IN:IOLCP
IOL Chemicals & Pharmaceuticals Ltd.
128.20
43.33
51.05%
IN:AARTIDRUGS
Aarti Drugs Limited
370.25
-68.50
-15.61%
IN:GRANULES
Granules India Limited
782.35
296.99
61.19%
IN:HIKAL
Hikal Limited
198.50
-159.88
-44.61%
IN:NEULANDLAB
Neuland Laboratories Ltd.
17,211.95
4,993.42
40.87%
IN:SOLARA
Solara Active Pharma Sciences Ltd.
567.95
37.25
7.02%
IOL Chemicals & Pharmaceuticals Ltd. Corporate Events
IOL Chemicals & Pharmaceuticals Publishes Audited FY26 Financial Results
May 21, 2026
IOL Chemicals Pharmaceuticals Ltd. published its audited standalone and consolidated financial results for the quarter and year ended 31 March 2026 in multiple leading business newspapers, in line with securities listing regulations. The results,...
IOL Chemicals Promoters Confirm No Encumbrance on Shares for FY 2026
May 4, 2026
Promoter Varinder Gupta has informed Indian stock exchanges that there are no encumbrances on the shares of IOL Chemicals Pharmaceuticals Ltd. held by him and the wider promoter group for the financial year ended 31 March 2026. The declaration, m...
IOL Chemicals & Pharmaceuticals Promoter Group Ups Stake Via Market Purchase
Mar 20, 2026
IOL Chemicals Pharmaceuticals Ltd. disclosed that promoter group entity NCVI Enterprises Ltd. has increased its shareholding in the company through an on-market purchase. NCVI acquired 404,305 equity shares on 19 March 2026, raising its stake fro...
IOL Chemicals & Pharmaceuticals Promoter Group Raises Stake via Market Purchase
Mar 19, 2026
IOL Chemicals and Pharmaceuticals Ltd. has disclosed a change in shareholding by promoter group entity NCVI Enterprises Ltd. under Regulation 7(2) of SEBI’s Prohibition of Insider Trading Regulations, 2015. The filing shows that NCVI Enterpr...
IOL Chemicals & Pharmaceuticals Defends Compliance of Q3 FY2025 Financial Results
Mar 17, 2026
IOL Chemicals Pharmaceuticals has clarified to the National Stock Exchange that its standalone and consolidated financial results for the quarter ended 31 December 2025 were prepared in full compliance with Indian Accounting Standards and the for...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.